Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-01

Study Completion Date

2030-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The MONIRITUX study aimed to evaluate whether monitoring (i) circulating B-cell reconstitution or (ii) serum rituximab levels could help identify relapse of autoimmune diseases in patients treated with rituximab. Retrospective data suggest that B-cell reconstitution or the appearance of anti-drug antibodies are associated with rituximab's failure to prevent relapses (i.e. rheumatoid arthritis, systemic lupus erythematosus, autoimmune cytopenia...). According to the routine care provided by our institution, patients undergoing rituximab therapy are monitored every three months during the first year after treatment induction and every six months thereafter. At each clinical visit, a blood test is performed to quantify total gammaglobulins, IgG and CD19+ cells (along with other tests depending on the disease). This study will use the remaining blood in the tubes from routine care to quantify CD27+ and CD38+ B cells, as well as serum rituximab and anti-rituximab antibodies, during the first year of follow-up. The primary outcome will be to identify risk factors for clinical relapse according to circulating B-cell or rituximab status.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

NCT06581562

Rheumatoid Arthritis Pemphigus Vulgaris Granulomatosis With Polyangiitis +1 more

RECRUITING PHASE1

Rituximab Vasculitis Maintenance Study

NCT01697267

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Microscopic Polyangiitis Wegener Granulomatosis

COMPLETED PHASE3

The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders

NCT00960713

Pemphigus Auto-immune Thrombocytopenic Purpura Hemolytic Auto-immune Anaemia +2 more

COMPLETED

RLIP76 in Human Serum in Adults With Rheumatologic Diseases

NCT00861159

Carotid Atherosclerosis

WITHDRAWN

Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis

NCT01773616

Systemic Lupus Erythematosus, Lupus Nephritis

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Cytopenia Connective Tissue Disorder Systemic Vasculitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Autoimmune cytopenia (immune thrombocytopenia or hemolytic anemia)

Blood CD19+, CD27+, and CD38+ B-cell reconstitution, circulanting rituximab level or the presence of circulating anti-rituximab antibodies will be compared in patients experiencing clinical relapse and those who will remain stable over time.

No interventions assigned to this group

Connective tissu disorder (SLE, myopathie, RA…)

Blood CD19+, CD27+, and CD38+ B-cell reconstitution, circulanting rituximab level or the presence of circulating anti-rituximab antibodies will be compared in patients experiencing clinical relapse and those who will remain stable over time.

No interventions assigned to this group

Systemic vasculitis (ANCA, essential cryoglobulinemia)

Blood CD19+, CD27+, and CD38+ B-cell reconstitution, circulanting rituximab level or the presence of circulating anti-rituximab antibodies will be compared in patients experiencing clinical relapse and those who will remain stable over time.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient who undergo rituximab treatment according to routine care and having one of the following disorder:
* primary immune thrombocytopenia
* primary autoimmune hemolytic anemia
* systmic lupus erythematous
* systemic sclerosis
* rheumatoid arthritis
* inflammatory myopathy
* ANCA associated vasculitis
* Cryoglobulinemic vasculitis